SCHEMBL6093390

SCHEMBL6093390

COC(=O)CN(C)S(=O)(=O)c1ccc(CBr)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 2/20 0.46
MMP13 P45452 2/20 0.46
MMP2 P08253 2/20 0.45
ADAM17 P78536 2/20 0.45
KMT2A Q03164 2/20 0.44
MAPK1 P28482 1/20 0.44
GAA P10253 2/20 0.44
ALDH1A1 P00352 4/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
RAB9A P51151 2/20 0.43
MEN1 O00255 1/20 0.43
KDM4E B2RXH2 2/20 0.42
NPC1 O15118 1/20 0.42
HPGD P15428 1/20 0.42
MMP1 P03956 1/20 0.41
MMP7 P09237 1/20 0.41
MMP8 P22894 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19900168 0.85 ALDH1A1 (0.58) MMP9MMP13MMP2ADAM17KMT2A
SCHEMBL570868 0.83 KMT2A (0.60) KMT2AMAPK1GAAALDH1A1SMN1; SMN2
SCHEMBL11580067 0.82 GAA (0.58) KMT2AGAAALDH1A1RAB9AMEN1
SCHEMBL15705805 0.79 MMP1 (0.51) MMP9MMP13MMP2ADAM17KMT2A
SCHEMBL15705781 0.78 KMT2A (0.52) KMT2AMAPK1GAAALDH1A1SMN1; SMN2
SCHEMBL15705731 0.78 GAA (0.54) KMT2AGAARAB9A
SCHEMBL26247380 0.78 MAPT (0.61) KMT2AGAAALDH1A1MEN1
SCHEMBL20323782 0.76 CASP3 (0.51) MMP13MMP2ADAM17MAPK1ALDH1A1
SCHEMBL20323781 0.75 ALDH1A1 (0.51) MMP9MMP13ADAM17KMT2AGAA
SCHEMBL12115465 0.74 KMT2A (0.47) KMT2AMAPK1GAAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060063828-A1 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof ATHEROGENICS, INC. 2006-03-23 US disclosed
WO-2006004903-A2 1,2-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND PHARMACEUTICAL COMPOSITIONS THEREOF ATHEROGENICS, INC. (US) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063828-A1 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof ABCB11, CEL, CYP46A1 MMP9 2936/4885MMP13 1596/4885MMP2 3465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.